Kathleen Drinan, DO
Cardiovascular Disease · Orland Park, ILNPI 1164417135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $178,830 of the $244,358 with a category attached, or 73.2%. 19 manufacturers reported payments, led by AstraZeneca at 53.2% of the total. Reporting peaked in 2019 at $91,538 and has fallen 83.1% since, to $15,427 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $644.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$130K
- Esperion Therapeutics, Inc.$76K
- Edwards Lifesciences$26K
- Novartis$8K
- Bayer$2K
- Amgen$366
- plus $2K from 13 others
What the payments were for
- Consulting fees$37,77515%
- Speaking & faculty fees$178,83073%
- Travel & lodging$17,7207%
- Food & beverage$9,9434%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 148 | $129,969 |
| Esperion Therapeutics, Inc. | 104 | $76,000 |
| Edwards Lifesciences | 28 | $26,362 |
| Novartis | 24 | $8,021 |
| Bayer | 3 | $1,649 |
| Amgen | 8 | $366 |
| Amarin Pharma, Inc. | 9 | $339 |
| Boehringer Ingelheim | 8 | $290 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $268 |
| E.r. Squibb & Sons, L.L.C. | 2 | $213 |
| Arbor Pharmaceuticals, Inc. | 12 | $182 |
| Cleerly, Inc. | 1 | $170 |
| Novo Nordisk | 2 | $133 |
| Johnson & Johnson | 14 | $116 |
| Akcea Therapeutics, Inc. | 1 | $99 |
| Abbott | 1 | $94 |
| Pfizer | 4 | $53 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$74,259
- NEXLETOL$74,259
- FARXIGA$63,608
- Edwards SAPIEN 3 Transcatheter Heart Valve$21,570
- LEQVIO$7,485
- Kerendia$1,649
- Vascepa$214
- Cleerly Ischemia$170
- Cleerly Labs$170
- Ozempic$121
- Repatha$118
- CAMZYOS$110
- JARDIANCE$102
How this compares
$244,358 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 240 | $322,075 |
| EntrestoSacubitril/Valsartan | 225 | $307,219 |
| JardianceEmpagliflozin | 116 | $184,156 |
| Repatha SureclickEvolocumab | 128 | $107,848 |
| FarxigaDapagliflozin Propanediol | 98 | $106,312 |
| XareltoRivaroxaban | 49 | $62,809 |
| Rosuvastatin Calcium | 1,286 | $21,358 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $18,848 |
| Praluent PenAlirocumab | 24 | $18,230 |
| DapagliflozinDapagliflozin Propanediol | 29 | $16,098 |
| Ezetimibe | 602 | $14,427 |
| VascepaIcosapent Ethyl | 11 | $10,915 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $8,200 |
| Metoprolol Succinate | 522 | $7,725 |
| Olmesartan Medoxomil | 343 | $7,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $322,075240 claims |
| NovartisEntresto | $8,021 | $307,219225 claims |
| Boehringer IngelheimJardiance | $290 | $184,156116 claims |
| AstraZenecaFarxiga | $129,969 | $106,31298 claims |
| Johnson & JohnsonXarelto | $116 | $62,80949 claims |
| Esperion Therapeutics, Inc.Nexlizet | $76,000 | $18,84816 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $182 | $8,20012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Orland Park
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.